GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BBT-369 overview

BBT-369 is under development for the treatment of relapsed and/or refractory B cell Non-Hodgkin's lymphoma including diffuse large B cell lymphoma (DLBCL), primary mediastinal (Thymic) large B cell lymphoma (PMBCL), high-grade B cell lymphoma (HGBCL), follicular Lymphoma (FL) and DLBCL transformed from FL.. The drug candidate comprises of autologous T- cells genetically modified to express chimeric antigen receptor (CAR). It is developed using MegaTAL gene-editing technology. It acts by targeting CD79a and CD20.

2Seventy Bio overview

2Seventy Bio discovers and develops new therapies for cancer treatment. 2Seventy Bio is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of BBT-369’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.